Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3476
Vitamin Cottage Natural Grocers
NGVC
$705M
| $886K | ﹤0.01% |
35,360
-22,889
| -39% | -$733K |
2016 Q2
38 quarters
|
|
3477
PUT
Doximity
DOCS
$4.98B
| $886K | ﹤0.01% |
+20,000
| New | +$1.12M |
2025 Q4
0 quarters
|
|
|
HTFL
3478
Heartflow Inc
HTFL
$4.29B
| $884K | ﹤0.01% |
30,336
+13,618
| +81% | +$438K |
2025 Q3
1 quarter
|
|
3479
PUT
Live Nation Entertainment
LYV
$39.3B
| $884K | ﹤0.01% |
6,200
| – | – |
2025 Q3
1 quarter
|
|
3480
Pacific Biosciences
PACB
$790M
| $883K | ﹤0.01% |
472,108
+72,201
| +18% | +$139K |
2013 Q2
50 quarters
|
|
3481
Tredegar Corp
TG
$245M
| $882K | ﹤0.01% |
122,808
+9,435
| +8% | +$71.5K |
2016 Q3
37 quarters
|
|
3482
CALL
Workday
WDAY
$44.9B
| $881K | ﹤0.01% |
4,100
| – | – |
2025 Q3
1 quarter
|
|
3483
Allogene Therapeutics
ALLO
$518M
| $880K | ﹤0.01% |
642,687
+43,690
| +7% | +$57.6K |
2018 Q4
28 quarters
|
|
3484
Cracker Barrel
CBRL
$1.25B
| $880K | ﹤0.01% |
34,656
+2,378
| +7% | +$76.1K |
2013 Q2
50 quarters
|
|
3485
FerroAtlántica
GSM
$796M
| $879K | ﹤0.01% |
189,524
+21,333
| +13% | +$98.5K |
2025 Q1
3 quarters
|
|
3486
Climb Global Solutions
CLMB
$612M
| $879K | ﹤0.01% |
34,212
+3,080
| +10% | +$89.4K |
2023 Q1
11 quarters
|
|
3487
Ranger Energy Services
RNGR
$366M
| $879K | ﹤0.01% |
62,854
+18,055
| +40% | +$245K |
2022 Q3
13 quarters
|
|
|
GOOD
3488
Gladstone Commercial Corp
GOOD
$626M
| $877K | ﹤0.01% |
82,229
+7,109
| +9% | +$79K |
2015 Q4
40 quarters
|
|
3489
Evolent Health
EVH
$391M
| $877K | ﹤0.01% |
219,141
+14,506
| +7% | +$80.6K |
2016 Q2
38 quarters
|
|
3490
Pearson
PSO
$9.69B
| $875K | ﹤0.01% |
+62,304
| New | +$862K |
2025 Q4
0 quarters
|
|
3491
BayCom
BCML
$341M
| $875K | ﹤0.01% |
29,748
+1,320
| +5% | +$38.1K |
2018 Q2
30 quarters
|
|
|
EU
3492
enCore Energy
EU
$198M
| $873K | ﹤0.01% |
352,127
+53,434
| +18% | +$153K |
2023 Q2
10 quarters
|
|
3493
Energy Vault
NRGV
$716M
| $872K | ﹤0.01% |
189,121
+189,119
| +9,455,950% | +$723K |
2022 Q2
14 quarters
|
|
3494
Eton Pharmaceutcials
ETON
$1.58B
| $870K | ﹤0.01% |
51,448
+14,642
| +40% | +$258K |
2024 Q4
4 quarters
|
|
3495
Evolus
EOLS
$472M
| $869K | ﹤0.01% |
130,738
+24,845
| +23% | +$168K |
2018 Q1
31 quarters
|
|
3496
Five Star Bancorp
FSBC
$1.07B
| $868K | ﹤0.01% |
24,252
+1,528
| +7% | +$53K |
2022 Q1
15 quarters
|
|
3497
Atea Pharmaceuticals
AVIR
$411M
| $867K | ﹤0.01% |
242,990
+1,526
| +0.6% | +$4.85K |
2022 Q1
15 quarters
|
|
3498
Enanta Pharmaceuticals
ENTA
$377M
| $867K | ﹤0.01% |
54,989
+13,368
| +32% | +$170K |
2013 Q2
50 quarters
|
|
3499
Liberty Media Corporation Series A Common Stock
FWONA
$20.9B
| $861K | ﹤0.01% |
9,636
+101
| +1% | +$9.06K |
2023 Q4
8 quarters
|
|
3500
PUT
Sarepta Therapeutics
SRPT
$1.85B
| $861K | ﹤0.01% |
40,000
-30,000
| -43% | -$632K |
2024 Q3
5 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.